Progress Pride flag bunting with the trans pink, blue and white chevron, illustrating Australia's new advice on puberty blockers

NewsroomTrans advocacyNews

Australia’s Top Research Body Backs Puberty Blockers as an Option

Australia's National Health and Medical Research Council released interim advice on Monday saying puberty blockers should remain a clinical option for some trans young people, chosen through shared decision-making.

Australia’s top health research body said on Monday that puberty blockers should remain a clinical option for some trans young people. The National Health and Medical Research Council released interim advice after a year-long review of the evidence, and it landed where many families hoped it would. The care should stay available, and it should be decided together by the young person, their parents or carers, and their clinicians.

The advice isn’t the final word, and it isn’t binding on Australia’s states. Within hours, Queensland and the Northern Territory said their limits on puberty blockers in public hospitals will stay. But in a year when the United Kingdom, Finland and many U.S. states have moved the other way, a national science agency weighing the same studies and recommending that the door stay open is news worth understanding.

01

What Australia’s NHMRC advised on puberty blockers

ABC News reported that the advice was released on Monday for public consultation. Health Minister Mark Butler had asked the NHMRC in 2025 to develop national guidelines for the care of trans and gender diverse young people, with priority interim advice on puberty blockers first.

Attitude reported that the document is titled “Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18.” It said submissions on the interim advice close on January 18, 2027.

The panel that wrote it, the Gender Guidelines Development Committee, made what’s called a conditional recommendation for using puberty blockers for certain young people, according to ABC. The committee suggested the medication could be considered for a young person with gender incongruence, with or without distress, who has been assessed as suitable for treatment and has begun puberty.

That last detail matters. OUTinPerth reported that, under the advice, a young person doesn’t need to express distress about their gender incongruence in order to access treatment. Care isn’t something a child has to suffer enough to earn.

02

What puberty blockers are, and why they’re debated

Puberty blockers are injections that pause aspects of physical development by suppressing sex hormones, ABC explained. Their clinical name is gonadotropin-releasing hormone analogues. They’ve been used since the 1980s to treat children who start puberty early, according to ABC, which is how doctors first came to know them well.

For trans young people, the idea is time. Advocates argue that pausing puberty temporarily gives a young person room to decide whether to take further steps, such as hormones. Critics, ABC reported, call the medication experimental and potentially dangerous. That disagreement has made puberty blockers one of the most argued-over treatments in medicine.

Gender incongruence is the clinical term for a difference between a person’s gender and the sex recorded at birth. Some people with gender incongruence also experience distress, known as gender dysphoria. The NHMRC’s advice keeps those two ideas separate, which is part of why its recommendation reads the way it does.

03

What the evidence review found

The NHMRC review included 15 non-randomised studies, most with follow-up of six months to two years, according to ABC. The committee rated the overall certainty of the evidence as low, because the studies were largely observational and generally short-term. It used a standard method for weighing evidence called GRADE.

Here’s what the reviewers found. The evidence showed that puberty blockers may improve psychosocial functioning and may reduce suicidality behaviours. The report said “serious adverse events are rare,” while advising that a young person on the medication should be monitored. The reviewers found no eligible evidence on fertility, fractures or other measures of bone health.

Why is the evidence so thin? ABC explained that randomised controlled trials raise ethical problems here, because they can mean delaying or withholding treatment from young people who need it. Blinded trials don’t work either, because the medication pauses visible changes, so participants can tell whether they’re receiving it.

The GRADE method sorts recommendations into five kinds, ABC explained, from “strongly for” to “strongly against.” A recommendation “conditionally for” a treatment means the benefits likely outweigh the harms and the best choice may depend on the individual patient. That’s where the NHMRC placed puberty blockers: not a default for everyone, and not a treatment to forbid.

The committee said conditional recommendations are more common than strong ones in clinical guidelines. In its words, “shared decision-making is essential” when different options may suit different people and when the certainty of evidence is low. “Both are the case here,” the report said, according to ABC.

04

What the advice asks of clinicians

The advice doesn’t hand out puberty blockers on request. Butler, quoted by Attitude, said decisions should be informed by appropriate information for the young person and their parents or carers, “a comprehensive health assessment, multidisciplinary input tailored by a healthcare team to the needs of the young person, and regular monitoring.”

That’s a high bar, and it’s the right one. A comprehensive assessment means a young person is seen as a whole person, not as a diagnosis. A multidisciplinary team means more than one professional looks at the decision. Regular monitoring means no one starts puberty blockers and is then left alone.

The evidence review backs that caution. The report advised that a young person using the medication “should be monitored for signs or symptoms that may warrant additional investigations and management,” ABC reported. The advice treats puberty blockers as serious medicine, given with care, and that’s how every family deserves to be treated.

Butler also spoke to the noise around the issue. “Not all of that public commentary and debate is always constructive,” he said, according to Attitude, adding that “sometimes it runs the risk of being quite damaging, particularly damaging to the mental health of those young Australians and their families.”

05

Who decides, and how

The heart of the advice is shared decision-making. Attitude quoted the council’s description: young people, their parents or carers and clinicians “discussing the available evidence, potential benefits and harms, and the young person’s individual circumstances and preferences before deciding together whether treatment is appropriate.”

The report put the principle simply, according to ABC: “care that is in one young person’s best interests may not suit another.” No one is promised puberty blockers. No one is forced onto them. The decision belongs to the people closest to the young person, with medical guidance at the table.

NHMRC Acting CEO Prue Torrance put it this way, as quoted by OUTinPerth and Attitude: “Puberty suppressants are one possible part of care.” She added that decisions “need to be made through shared decision-making that involves the individual young person, their parents or carers and clinicians.”

OUTinPerth also reported a finding that families will recognise. Withholding care to “wait and see” as puberty progresses, the advice says, “can affect the young person’s physical and mental health, wellbeing, and ability to function.” Waiting isn’t neutral. It has costs too.

06

Queensland and the Northern Territory say no

Because the NHMRC’s guidance is advisory, Australia’s states and territories decide how to use it. Queensland restricted puberty blockers in its public system last year for young people not already on them, and the Northern Territory banned them in its public system for people under 18, ABC reported.

Queensland Health Minister Tim Nicholls said the state had already made “a clear decision” after its own independent review. “Our position remains unchanged, and we will continue to prioritise the health, safety and wellbeing of young Queenslanders,” he said. ABC reported that Queensland will keep its pause until 2031 while it waits for a delayed UK trial known as PATHWAYS.

Even Queensland’s own review found more nuance than its policy suggests. As it paused access, Queensland ordered an independent review by psychiatrist Ruth Vine. ABC reported the review found the evidence on puberty blockers and fertility was limited and that bone health could be affected in the short to medium term. It also found the effects were “reversible” and that, with proper oversight, “there can be benefit for a young person.”

A Northern Territory spokesperson said its position was “unchanged.” “Our decision is consistent with Queensland, the United Kingdom and Finland, which have all taken a cautious approach,” the spokesperson said.

Butler said he expects every state to weigh the advice. “I’m very confident that every state government, no matter their political persuasion, will consider the advice of our pre-eminent authority very closely,” he told ABC. Whether Queensland or the Northern Territory changes course, he said, “is really a matter for them.”

Equality Australia CEO Anna Brown called for both governments to lift their bans. “No young person’s access to clinically appropriate healthcare should depend on which state they live in,” she said, according to OUTinPerth.

07

How Australia fits the global picture

Australia’s advice arrives in a divided world. ABC noted that the UK, Finland and many U.S. states have moved to restrict puberty blockers. Across the Tasman, New Zealand’s government banned new prescriptions last year, but the country’s High Court recently ruled the regulations unlawful, so doctors there can prescribe them again, ABC reported.

The NHMRC didn’t claim the evidence is strong. It said the opposite, plainly. What it did was ask a different question: given low-certainty evidence, should the choice be taken away from every family, or left to each family with their clinicians? Its answer was the second.

It’s also worth knowing how common conditional recommendations are. ABC reported that the Endocrine Society recently reviewed puberty blockers for children who go through puberty early, a use no one calls controversial. It, too, made a conditional recommendation, based on very low certainty evidence. Low certainty isn’t the same as danger; it’s often the honest state of pediatric medicine.

Community groups in Australia welcomed the advice, OUTinPerth reported. Equality Australia’s Anna Brown said it “reinforces that the care trans young people are receiving in Australia today is grounded in evidence”. The advice also noted that published data indicates only a small number of young Australians are accessing this care, OUTinPerth reported.

That’s a careful answer, and it isn’t the same as saying puberty blockers are right for everyone. It’s a recognition that young people differ, that families differ, and that a blanket ban removes a choice the evidence doesn’t rule out.

08

What it means for families in the U.S.

Australia’s advice doesn’t change any American law. But families here are living with decisions made on the same thin evidence base. Bloom has reported on the federal government’s move to cut Medicaid funding for gender-affirming care for people under 18, a rule now being fought in court.

When American officials say the evidence on puberty blockers is too weak to allow, it’s worth knowing that Australia’s national research body read low-certainty evidence and still recommended keeping the option, with safeguards and monitoring. Bloom has also reported on new research finding that transition regret is rare. Neither study nor advice settles every question. Both belong in the conversation.

If you’re a parent, the most useful thing in this advice may be its process. It asks for a comprehensive health assessment, input from a team, and regular monitoring. Those are questions you can bring to any clinician: who’s on the team, how often will my child be checked, and how will we decide together?

And if you’re a young person reading this, hear it plainly. Your questions about your body and your future are real, and they deserve real answers from people who take you seriously. Whatever you and your family decide about puberty blockers, or about anything else, you’re allowed to take your time, ask every question and be cared for while you do.

09

What’s still unclear

It’s unclear whether any state will change its rules because of the advice. Queensland and the Northern Territory have said no, at least for now.

It’s also unclear when the final guidelines will arrive. ABC reported the full national guidelines are due in 2028, while OUTinPerth reported the full report is expected in late 2027. Bloom will report the date when the NHMRC confirms it.

The interim advice is public while it’s open for consultation, so anyone can read what the committee found before the final version is written. The final guidelines will show whether public submissions changed it.

Finally, the consultation could change the wording. The advice is interim, and submissions are open until January 18, 2027, according to Attitude. Bloom will follow the final text of the advice on puberty blockers.

10

What Bloom is doing

Bloom exists so that trans young people and their families never face these questions alone. If today’s news stirs up fear or grief for you, Bloom’s crisis support page lists people you can reach now: The Trevor Project at 1-866-488-7386, Trans Lifeline at 877-565-8860, and 988 by call or text.

Bloom will read the final NHMRC guidelines when they’re published and report what changed from this interim advice on puberty blockers, line by line.

Families looking for others who understand can find Bloom’s support groups. And Bloom Resources, our coming library of verified, dated and primary-sourced guides for trans and disabled people, will hold a plain-language guide to the evidence on youth care, so parents can read the studies for themselves.

This work runs on people who give a little every month. Become a monthly supporter, or give once if that fits your life better.

11

Frequently Asked Questions

Its interim advice says puberty blockers should remain a clinical option for some trans young people who have begun puberty and are assessed as suitable, chosen through shared decision-making with families and clinicians.

No. It’s advisory, so each state and territory decides how to use it. Queensland and the Northern Territory have said their restrictions will stay.

The NHMRC rated the overall certainty of the evidence as low. Its review of 15 studies found puberty blockers may improve psychosocial functioning and may reduce suicidality behaviours, and that serious adverse events are rare.

No. OUTinPerth reported that the advice says a young person doesn’t need to express distress about their gender incongruence to access treatment.

Attitude reported that submissions on the interim advice close on January 18, 2027.

Not directly. American laws and federal rules are unchanged. The advice does give families and clinicians here another national review to consider when they weigh puberty blockers.

Bloom’s crisis support page lists The Trevor Project, Trans Lifeline and 988. Bloom’s support groups are open to trans people and the families who love them.

Queensland paused access in its public system for young people not already on them and ordered an independent review. That review found limited evidence but said the effects were reversible and that, with oversight, there can be benefit.

Sovereignty over Servitude. 🌸

Support this work

Everything Bloom publishes is free to read and free to share.

Bloom Ministries is a registered 501(c)(3) in Salem, Oregon. Monthly giving is what lets us say yes before the money is in hand.

Give monthlyGive onceGifts are tax-deductible to the extent allowed by law.